Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Implant or insert
Reexamination Certificate
2001-07-05
2004-07-27
Azpuru, Carlos A. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Implant or insert
C424S078080, C424S078090, C424S078310
Reexamination Certificate
active
06767552
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of Invention
According to the present invention, any suitable application can be used to apply the composition to the affected areas of. Suitable applicators and pack again systems are disclosed in, for example, U.S. Pat. No. 5,928,611 and U.S. patent applications Ser. Nos. 09/430,177, 09/430,176, 09/430,289, 09/430,290, and 09/430,180 filed Oct. 29, 1999; Ser. No. 09/343,914 filed Jun. 30, 1999; Ser. No. 09/385,030 filed Aug. 30, 1999; and Ser. No. 09/176,889 filed Oct. 22, 1998; the entire disclosures of which are incorporated herein by reference. A further further suitable application is described in co-pending U.S. patent application Ser. No. 09/898,006, filed concurrently herewith, the entire disclosures of which are incorporated herein by reference.
2. Description of Related Art
Monomer and polymer adhesives are used in both industrial (including household) and medical applications. Included among these adhesives are the 1,1-disubstituted ethylene monomers and polymers, such as the &agr;-cyanoacrylates. Since the discovery of the adhesive properties of such monomers and polymers, they have found wide use due to the speed with which they cure, the strength of the resulting bond formed, and their relative ease of use. These characteristics have made the &agr;-cyanoacrylate adhesives the primary choice for numerous applications such as bonding plastics, rubbers, glass, metals, wood, and, more recently, biological tissues.
It is known that monomeric forms of &agr;-cyanoacrylates are extremely reactive, polymerizing rapidly in the presence of even minute amounts of an initiator, including moisture present in the air or on moist surfaces such as animal (including human) tissue. Monomers of &agr;-cyanoacrylates are anionically polymerizable or free radical polymerizable, or polymerizable by zwitterion or ion pairs to form polymers. Once polymerization has been initiated, the cure rate can be very rapid.
Medical applications of 1,1-disubstituted ethylene adhesive compositions include use as an alternate or an adjunct to surgical sutures and/or staples in wound closure, as well as for covering and protecting surface wounds such as lacerations, abrasions, burns, stomatitis, sores, minor cuts and scrapes, and other wounds. When an adhesive is applied to surfaces to be joined, it is usually applied in its monomeric form, and the resultant polymerization gives rise to the desired adhesive bond.
U.S. Pat. Nos. 5,514,371, 5,514,372, 5,575,997, 5,624,669, and 5,582,834 to Leung et al. disclose the addition of a therapeutic agent in a cyanoacrylate composition. The cyanoacrylate adhesive forms a matrix for the therapeutic agent, with the therapeutic agent being released in vivo over time from the matrix during biodegradation of the polymer.
U.S. Pat. No. 5,762,955 to Smith discloses a treatment for healthy, damaged, diseased, or infected biological tissue by applying a bioadhesive coating in conjunction with a medication. The treatment is directed, in part, to treating external biological tissue that may be affected by harmful afflictions such as bruises, burns, dermatological afflictions, infections, gashes, wounds, herpes sores, canker sores, or intra-oral lesions, and skin cancers such as leukemia. Smith further discloses several medications that may be used including corticosteroids, fluoroouracil, obtundants, anesthetics, antibiotics, fungicides, anti-inflammatory agents, antibacterial agents, antiseptic agents, and other medications or combinations of medications used in processes for healing tissue, promoting or preventing blood clotting, destroying cancer cells, palliative treatments and killing of bacteria or viruses.
U.S. Pat. No. 4,880,416 to Horiuchi et al., discloses a dermal bandage of a pre-formed film-like adhesive material for preventing dermally applied ointments, creams, solutions, powders, etc. from falling off, and for delivering drugs, such as anti-fungal agents, to affected parts of the skin. U.S. Pat. Nos. 5,716,607 and 5,716,608, both to Byram et al., disclose the use of cyanoacrylate adhesives to prevent ionization radiation damage to skin. Such damage is prevented by applying the cyanoacrylate polymer to the skin to be protected. U.S. Pat. No. 5,653,769 to Barkey, Jr., et al., discloses protecting skin areas from irritation due to contact with artificial devices such as prosthetics, bandages and casts by applying a cyanoacrylate polymer to the desired skin areas that otherwise would be prone to ulceration or irritation by the devices.
U.S. Pat. No. 4,287,177 to Nakashima et al. discloses a protective covering material for forming a film or coat on the skin or wound surface, wherein the film may contain an anti-fungal agent that is controllably released when the composition is placed in contact with the skin. U.S. Pat. Nos. 5,684,042; 5,753,699; 5,762,919; 5,783,177; and 5,811,091 to Greff et al. disclose a cyanoacrylate composition with a compatible anti-fungal agent to form an anti-fungal polymeric cyanoacrylate film to be applied on mammalian skin as wound dressings, wound bandages, surgical incise drapes, wound closure materials and the like.
Oral candidiasis is a yeast infection of the mouth, especially of the mucous membranes of the mouth and tongue, generally caused by fungal species of
Candida albicans
. This fungal species, or similar species, also cause similar and related fungal infections in the mouth. The condition generally includes the appearance of whitish velvety plaques on the mucous membranes of the mouth and/or tongue. If the whitish plaques are scraped away, the underlying base may be red (erythematous) with pinpoint bleeding. Oral candidiasis, sometimes referred to as adult oral thrush, and related or similar oral fungal infections, are common occurrences in infants where they do not pose a serious concern. However, the occurrence of such oral infections in adults is considered abnormal, and generally occurs only when conditions that depress the immune system are present. That is, the presence of the fungal species in healthy individuals is kept in balance by the presence of other bacteria in the mouth. However, when this balance is upset, the fungal species may grow out of control. For example, such oral infections are common in patients that are infected with the AIDS virus, in patients under immunosuppression for organ transplant, individuals undergoing chemotherapy, patients with diabetes, patients of advanced age or general poor health, and individuals having inherited abnormalities of the immune system. The occurrence of such oral infections may also occur in individuals where the balance of normal microorganisms is upset, such as by the use of antibiotics, excessive use of mouthwash or mouth sprays, long-term use of corticosteroids or immunosuppressive medications, uncontrolled diabetes mellitus, or with normal hormone changes associated with pregnancy or the use of birth control pills.
In the case of immunocompromised people, the infection may be massive, coating much of the surface of the mouth and tongue. In addition, it may spread to the esophagus, producing esophagitis candida with resulting painful difficult swallowing.
Because the conditions oral candidiasis and esophagitis candida are related in terms of their origins, “oral” infections, as used herein, is intended to cover infections not only of the oral cavity (such as the mouth and tongue) but also of the esophagus. However, “oral” infections in the context of the present invention is not intended to cover infections of other bodily areas caused by the same or similar microorganisms, such as candidal vulvovaginitis or vaginal yeast infections.
Furthermore, based on the similarity between fungal infections and yeast infections, particularly in terms of their causes, “fungal infection” as used herein is intended to mean fungal and/or yeast infections, unless noted otherwise.
The incidence of oral candidiasis in adults has increased dramatically with the spread of AIDS. HIV infected people are at high risk for oral candidiasis, which oft
Azpuru Carlos A.
Closure Medical Corporation
Oliff & Berridg,e PLC
LandOfFree
Adhesive treatment for oral fungal infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adhesive treatment for oral fungal infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adhesive treatment for oral fungal infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3196613